Iuga et al.[29] reported that Lgr5 was a novel IHC marker for gastrointestinal neuroendocrine tumors; 88% of primary neuroendocrine tumors and 87% of metastases stained positive for cytoplasmic Lgr5. This evidence concerns the gene LGR5 and digestive system neuroendocrine tumor, grade 1/2.